comprehensive -WSS

comprehensive

author：focus 2025-10-02 00:43:18 - browse：968

Sarepta - Cambridge -AP — Kristoffer Tripplaar/Sipa via AP

The Food and Drug Administration granted conditional approval Thursday to the first gene therapy for Duchenne muscular dystrophy. Regulators restricted the treatment to younger patients, with additional data required to broaden its use.

The gene therapy, called Elevydis, is made by Sarepta Therapeutics. The company will charge $3.2 million for the treatment, making it the U.S.’s second most expensive drug, behind a recently approved gene therapy for hemophilia. CEO Doug Ingram said on a conference call the price was below what a recently published company-funded analysis found would be cost-effective.

“The approval of Elevidys is a watershed moment for the treatment of Duchenne. Elevydis is the first and only gene therapy approved for Duchenne, and this approval brings us closer to our goal of bringing forward a treatment that provides the potential to alter the trajectory of this degenerative disease,” Ingram said.

Unlock this article by subscribing to STAT+ and enjoy your first 30 days free!

GET STARTED Log In

Previous article： DIEP, the 'gold standard' of breast reconstruction, is under threat
Next article： Readout Newsletter: The latest on Novavax, Merck, Bluebird

knowledge

WSS

Reconstructing family trees of blood cells may help predict disease

Medicare Advantage insurers face 0.2% cut to 2025 payments

Why a market frenzy over new weight loss drugs defies logic

UnitedHealth, Optum discontinue NaviHealth name

Venture capital firm's plans to take over Akron hospital face hurdles

Merck, Daiichi strike cancer drug pact worth up to $22 billion

leisure time

comprehensive

explore

Cancer drug shortages should be causing more outrage

Readout LOUD podcast: Live from the 2023 STAT Summit

In age of alternative facts, a scholarly course on calling out crap

Health tech investors get more selective as pandemic boom fades

Guidelines to prevent youth baseball injuries need more muscle

UnitedHealth, Optum discontinue NaviHealth name

United colonoscopy coverage change 'may cost lives,' doctors say

Philips to halt sales of sleep apnea machines in U.S.

Activists slam private health insurers over coverage restrictions

STAT Summit: Ending the crisis of Black deaths in the U.S.

hotspot

STAT Summit: Doctor v. ChatGPT showed AI's promise, blind spots

Roche acquires Telavant from Roivant, adding experimental IBD treatment

Harvard's Jason Buenrostro wins MacArthur grant for genetics work

STAT Summit: Doctor v. ChatGPT showed AI's promise, blind spots

Cassava Sciences’ Alzheimer’s clinical trials should be halted

Why Medicare shouldn’t cover every FDA

knowledge

hotspot

entertainment

hotspot